Severe Single-Gene Disorders & Multi-System Deletions

Rett Syndrome

MECP2 Mutation X-Linked Neurodevelopmental Regression Disorder

Primary risk age: Infants and toddlers (typically recognized between 6 to 18 months; almost exclusively in girls)

Urgency: Severe
Typical age: Infants and toddlers (typically recognized between 6 to 18 months; almost exclusively in girls)
Body system: Genetic & Chromosomal

Typical course: This is a progressive neurodevelopmental genetic disorder; management is continuous and supportive.

Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13

1. Summary & Pathophysiology

MECP2 Mutation X-Linked Neurodevelopmental Regression Disorder

Pathophysiology (Development Path)

MECP2 protein deficiency impairs chromatin remodeling and transcriptional control in mature neurons, causing progressive microcephaly, loss of synaptic connections, and severe motor and autonomic regression.

Primary Causes & Etiology

Mutations in the MECP2 gene on the X chromosome (essential for brain development and transcriptional regulation).

2. Symptom Continuum

Early Onset Signs
Apparently normal development until 6–18 months, followed by a deceleration of head growth and developmental flattening.
Progressive Phase
Rapid regression of acquired motor skills and spoken language. Loss of purposeful hand skills, replaced by stereotypic hand movements (wringing, hand washing).
Severe Indicators
Complete loss of spoken language, severe scoliosis, breathing irregularities (hyperventilation and apnea episodes at rest), seizures, and loss of walking ability.

3. Clinical Verification

Genetic testing showing mutation in the MECP2 gene. Clinical diagnosis based on diagnostic criteria (hand stereotypies, motor regression).

4. Care & Elements Plan

Primary Care Treatment Plan

Supportive and palliative framework. Provide physical and occupational therapy to maintain joint mobility. Manage seizures and breathing abnormalities. Nutritional support (feeding tube if dysphagia is severe).

Home Support Elements

Monitor for breathing abnormalities and manage seizures. Position the child carefully to prevent scoliosis progression. Encourage non-verbal communication (eye-gaze boards).

Generic Active Ingredients (No Brands)

Trofinetide (first FDA-approved active drug to treat core symptoms of Rett syndrome)
Valproic acid or Levetiracetam (generic antiepileptics to manage seizures).

Lists active elements only. Never administer self-designed therapies.

5. Doctor Critical Lines

Critical Thresholds: When to See a Doctor

Seek immediate evaluation if a previously normal infant begins losing hand skills, stops babbling, or exhibits repetitive hand wringing.

6. Vaccine & Prevention

Routine Prophylaxis (Prevention)

No prevention is possible, as the mutation is almost always a random de novo somatic event.

Immunization Context

No specific immunizations are associated; follow standard schedules.

7. Timelines & Outlook

Active Timeline

This is a progressive neurodevelopmental genetic disorder; management is continuous and supportive.

Expected Prognosis

Guarded. While most girls survive to adulthood, they remain severely disabled and require lifelong constant care.

Potential Untreated Complications

Seizures, severe scoliosis, prolonged QT interval (sudden cardiac death risk), dysphagia, and aspiration pneumonia.

Severe

Cystic Fibrosis (CF)

Autosomal Recessive Multi-System Exocrine Disorder

Infancy through Adulthood (Screened at birth; symptoms develop in infancy)

Moderate

Williams Syndrome

Autosomal Dominant Microdeletion Syndrome

Apparent in infancy and early childhood (Lifelong condition)